Key facts
- It has raised $134.3M across 1 recorded rounds; the latest was Seed Round ($4.3M) in May 2022.
- Notable investors include Oak HC/FT, Oxeon Partners, Martin Ventures, Rubicon Founders, Balboa Nephrology — 8 tracked in total.
- Evergreen Nephrology has filed 1 Form D with the SEC, most recently Jun 2022 ($4.3M sold to 335 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Evergreen Nephrology
Funding rounds
1 roundsAbout Evergreen Nephrology
Provider of chronic care management services intended to serve people suffering from kidney disease. The company offers an improved kidney care experience for patients by delaying disease progression, shifting kidney care home and getting patients who need organ transplants and dialysis care, enabling nephrologists to transform kidney care and improve patient quality of life.
- Sector
- Healthcare
- HQ
- Nashville, TN, United States
- Founded
- 2021
- Employees
- 220
- Website
- egneph.com/
- Ownership
- Privately Held (backing)
Evergreen Nephrology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Evergreen Nephrology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Evergreen Nephrology in its N-PORT filings yet. We sweep new filings monthly.